, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, supported by BeiGene, we had the pleasure of speaking with Mazyar Shadman, MD, MPH, about updates in zanubrutinib (Brukinsa)–focused research in chronic lymphocytic leukemia (CLL) that were presented at the 2024 ASH Annual Meeting. Dr Shadman is an associate professor in the Clinical Research Division and the medical director of Cellular Immunotherapy at the Fred Hutchinson Cancer Center in Seattle, Washington.

In our exclusive interview, Dr Shadman discussed key findings and implications from several clinical trials investigating zanubrutinib as monotherapy and in combination with agents such as obinutuzumab (Gazyva), sonrotoclax (BGB-11417), and venetoclax (Venclexta) in patients with CLL and other B-cell malignancies.

That’s all we have for today! Thank you for listening to this episode of 

, supported by BeiGene. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

 is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Podcasts

Dr Shadman discusses key findings and implications from trials that were presented at the 2024 ASH Annual Meeting investigating zanubrutinib in CLL.

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

In today’s episode, supported by BeiGene, Alexey Danilov, MD, PhD, hosted a discussion with Nicole Lamanna, MD, about the use of zanubrutinib (Brukinsa) in patients with chronic lymphocytic leukemia (CLL). Dr Danilov is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, the medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma at the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. Dr Lamanna is an associate clinical professor of medicine in the Hematologic Malignancies Section of the Hematology/Oncology Division at the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York. 

In our exclusive interview, Drs Danilov and Lamanna discussed key efficacy data from the final comparative analysis of the phase 3 ALPINE trial (NCT03734016) in patients with relapsed/refractory CLL, zanubrutinib-associated toxicities to consider when using this agent, and what the future looks like for BTK inhibitor–based therapy in CLL.

Drs Danilov and Lamanna discuss key efficacy data from the final comparative analysis of the ALPINE trial of zanubrutinib in relapsed/refractory CLL.

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

Experts detail updates regarding BTK inhibitors in chronic lymphocytic leukemia around the 2024 ASH Annual Meeting.

Updates for BTK Inhibitors in CLL Around ASH 2024 | Supplements and Featured Publications

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD